Zafemy Shortage: What Providers and Prescribers Need to Know in 2026

Patients are calling your practice because they can't fill their Zafemy prescription. As a prescriber, you need actionable information — not a simple "it's not in shortage" reassurance. This guide covers the current availability landscape for Zafemy, the most appropriate therapeutic alternatives, prescribing workflow adjustments, and counseling language to help your patients navigate stocking gaps.

Current Availability Status (2026)

Zafemy (norelgestromin 150 mcg/day / ethinyl estradiol 35 mcg/day transdermal system) is not listed on the FDA Drug Shortage Database as of 2026. The drug is manufactured solely by Amneal Pharmaceuticals LLC and distributed through AvKARE. The ASHP drug shortages database also does not list Zafemy as a current shortage.

However, your patients are experiencing a real problem: localized stocking gaps. These occur because (a) Zafemy is a single-source generic, (b) it launched in 2021 and its distribution infrastructure is still less mature than Xulane's, (c) some pharmacy chains prefer stocking Xulane due to existing wholesaler contracts, and (d) low retail volume at individual pharmacy locations means intermittent ordering.

Therapeutic Equivalents: What to Prescribe Instead

When Zafemy is unavailable, the following alternatives should be considered in order of similarity:

1. Xulane (norelgestromin/ethinyl estradiol transdermal system)

Xulane is the FDA-designated AB-rated therapeutic equivalent to Zafemy. Both deliver 150 mcg/day norelgestromin and 35 mcg/day ethinyl estradiol. The only difference is patch size (Xulane: 14 cm²; Zafemy: 12.5 cm²). Pharmacokinetic data demonstrate bioequivalence. For patients on Zafemy who cannot find it, switching to Xulane does not require a therapeutic substitution discussion — it is a pharmaceutical equivalent switch.

Note: Xulane is manufactured by Viatris (formerly Mylan Pharmaceuticals). It carries the same boxed warning regarding cigarette smoking and cardiovascular events, and the same BMI ≥ 30 kg/m² contraindication.

2. Twirla (levonorgestrel/ethinyl estradiol transdermal system)

Twirla delivers 120 mcg/day levonorgestrel and 30 mcg/day ethinyl estradiol — a different progestin and lower estrogen dose. It is also contraindicated in BMI ≥ 30 kg/m² (with an intermediate BMI zone of 25–30 showing reduced efficacy). Twirla is not bioequivalent to Zafemy but is an appropriate alternative for patients requiring a patch who cannot access Zafemy or Xulane. It requires a new prescription and patient counseling on the different hormone profile.

3. Combined Oral Contraceptives

If the patient is willing to transition to an oral method, COCs containing norgestimate/ethinyl estradiol (e.g., Sprintec, Ortho Tri-Cyclen generics) or levonorgestrel/ethinyl estradiol are appropriate alternatives. Counsel patients that pills require daily adherence and that they should use backup contraception for 7 days when starting a new pack after a lapse in patch use.

Formulary and Prior Authorization Considerations

Under the ACA's contraceptive coverage mandate, most non-grandfathered insurance plans must cover at least one product in each FDA-approved contraceptive category at no cost to the patient. However, plans are not required to cover every brand or generic — only at least one in each category.

Clinical scenarios you may encounter:

Plan covers Zafemy but not Xulane: Submit a formulary exception citing unavailability. Include a note that Xulane is bioequivalent and the patient's Zafemy is unobtainable.

Plan covers Xulane but not Zafemy: Switch directly to Xulane; no PA needed in most cases since it's the same hormone class and typically covered as the formulary preferred product.

Neither covered: Rare under ACA, but possible in grandfathered plans. Patient may qualify for manufacturer savings cards or patient assistance programs — see our savings guide for details.

Prescribing Workflow Recommendations

To minimize callbacks and prescription delays for your Zafemy patients, consider these workflow adjustments:

Write Zafemy/Xulane interchangeable: In your e-prescribing system, consider adding "may dispense Xulane" in the sig notes so the pharmacist can fill whichever is in stock without calling you.

90-day supply prescriptions: A 3-month supply reduces fill frequency and lowers the chance of a patient running out during a local stock gap.

Mail-order referrals: Proactively recommend mail-order pharmacy (Amazon Pharmacy, CVS Caremark Mail Service, etc.) for patients who have had stocking issues in the past.

Recommend medfinder:[@portabletext/react] Unknown block type "span", specify a component for it in the `components.types` prop helps your patients locate in-stock Zafemy at pharmacies near them, reducing the number of prior authorization requests and callback calls to your office.

Patient Counseling Language for Stocking Gaps

When counseling patients about a Zafemy stocking issue, consider the following language:

"Zafemy and Xulane contain the exact same hormones at the same doses. Your prescriber can easily switch you — it's the same medication in a slightly larger patch."

"If your patch has been off for more than 48 hours, restart your cycle and use backup contraception for 7 days. Call us if you need clarity on what to do next."

"Use medfinder.com to have pharmacies near you called on your behalf — it saves you from spending an hour on hold."

Summary for Prescribers

Zafemy is not in an official shortage, but localized availability gaps are frequent. The best clinical response is to have a ready substitute (Xulane) and a streamlined PA workflow for formulary exceptions. Direct your patients to medfinder for providers to reduce call volume to your office and help patients locate in-stock medication faster.